WO2001079211A1 - Procede de preparation d'un compose 3-vinylcepheme - Google Patents
Procede de preparation d'un compose 3-vinylcepheme Download PDFInfo
- Publication number
- WO2001079211A1 WO2001079211A1 PCT/JP2001/003182 JP0103182W WO0179211A1 WO 2001079211 A1 WO2001079211 A1 WO 2001079211A1 JP 0103182 W JP0103182 W JP 0103182W WO 0179211 A1 WO0179211 A1 WO 0179211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- compound
- formula
- production method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a method for producing a Cefdir compound widely used as an oral antibiotic.
- Cefdinir compounds are usually derived in a form in which at least one of an amino group, an oxime hydroxyl group and a hydroxyl group is protected. These undergo a deprotection reaction in the final step. (6R, 7R) -13-vinyl-8-oxo-17-[(Z) -2-((2-amino- 4-thiazolyl) -12-hydroxyiminoacetamide] It is led to 11-aza-5-thiabicyclo [4.2.0] octane-2-carboxylic acid (Cefdinir). However, deprotection methods for these compounds have not yet been established for cefdinir compounds having various functional groups in the molecule. For example, in Japanese Patent Publication No.
- the method using aluminum chloride in the presence of anisol cannot be applied to the synthesis of cefdiryl due to the high acidity of aluminum chloride.
- the reaction cannot proceed with good yield with cefdiryl which is unstable under strongly acidic conditions.
- the final cefdinir becomes a hydroxyl group in the oxime group, so that in the presence of a large amount of protonic acid or strong Lewis acid, isomerization of syn-anti proceeds to increase inappropriate impurities. Therefore, these deprotection methods cannot be used.
- An object of the present invention is to efficiently produce a 3-vinyl-cephem compound represented by the formula (2) from a protected 3-vinyl-cephem derivative represented by the formula (1) without using an expensive reagent. It is to provide a new technology. Disclosure of the invention The present invention provides a 3-vinyl-cephem compound represented by the formula (2) by treating a protected 3-vinyl-cephem derivative represented by the formula (1) in an organic solvent in the presence of a perhalogenated acid and an organic protonic acid. And a method for producing a 3-vinyl-ceph compound.
- R 1 , R 2 and R 3 represent a hydrogen atom or an arylmethyl group which may have a substituent. However, R 1 , R 2 and R 3 are not hydrogen atoms at the same time.
- an organic protonic acid that is weak against amide groups and amino groups in the raw material skeleton is used in an organic solvent.
- By hydrogen bonding and using only the required amount of strong perhalogenated acid it became possible to synthesize cefdinir compounds stably and in good yield.
- this reaction only a necessary minimum amount of a strong perhaptic genated acid that can contribute to the reaction is used, so that a cefdiryl compound can be stably present in the reaction system.
- the optionally substituted arylmethyl group represented by R 1 R 2 or R 3 may be a benzyl group, a diphenylmethyl group, a trityl group, an anisylmethyl group, a naphthyl group which may have a substituent. Represents a methyl group or the like.
- substituents which may be substituted include a hydroxy group, a lower alkyl group having 1 to 4 carbon atoms such as methyl, ethyl and tert-butyl, and a lower alkoxy group having 1 to 4 carbon atoms such as methoxy and ethoxy.
- the diphenylmethyl group includes those in which a substituted or unsubstituted phenyl group is bonded in the molecule via a methylene chain or a hetero atom.
- benzyl p-methoxybenzyl, diphenylmethyl, trityl, 3,4,5-trimethoxybenzyl, 3,5-dimethoxy-4-hydroxybenzyl, 2,4,6-trimethylbenzyl And a ditolylmethyl group.
- organic protonic acid that can be used in the present invention, those having a pKa of 3 to 5 are preferred, for example, substituted or unsubstituted substituted or unsubstituted acids such as formic acid, acetic acid, chloroacetic acid, propionic acid and 2-ethylhexanoic acid
- substituted or unsubstituted substituted or unsubstituted acids such as formic acid, acetic acid, chloroacetic acid, propionic acid and 2-ethylhexanoic acid
- substituted or unsubstituted substituted or unsubstituted acids such as formic acid, acetic acid, chloroacetic acid, propionic acid and 2-ethylhexanoic acid
- substituted or unsubstituted substituted or unsubstituted aromatic sulfonic acids such as lower alkyl carboxylic acid, benzoic acid, and toluic acid can be widely used.
- the amount of the organic protonic acid to be used is generally 1 to 20 molar equivalents, preferably 2.5 to 10 molar equivalents, particularly preferably 3 to 5 molar equivalents, based on the compound of the above formula (1). It is.
- the perhalogenated acid examples include perchloric acid, periodic acid, and perbromic acid.
- the catalyst may be used in an amount of usually a catalyst, but it is preferably used in an amount of usually 0.1 to 5 times the molar equivalent of the compound of the formula (1).
- the concentration of the perhalogenated acid a commercially available product having a concentration of 60% can be used as it is, but it can also be used after diluting it in the range of 10 to 50% depending on the reaction system.
- the organic solvent that can be used in the present invention include methyl formate, ethyl formate, propyl formate, butyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, and propyl acetate.
- Lower alkyl esters of lower carboxylic acids such as methyl onate and ethyl propionate; ketones such as acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, and getyl ketone; acetonitrile, propionitrile; Nitriles such as butyronitrile, isoptyronitrile, and valeronitrile; substituted or unsubstituted aromatic hydrocarbons such as benzene, toluene, xylene, chlorobenzene, and anisol; dichloromethane, chloroform, dichloroethane, and trichloroethane.
- ketones such as acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, and getyl ketone
- Particularly preferred solvents include benzene, toluene, xylene, dichloromethane, chloroform, and dichloromethane. These are used alone or in combination of two or more. Further, these organic solvents may contain water as necessary.
- solvents are usually used in an amount of about 2 to 200 L, preferably about 3 to 100 L per kg of the compound of the formula (1).
- the reaction is carried out at a temperature in the range of ⁇ 20 to 100 ° C., preferably 0 to 50 ° C. .
- the compound of the formula (2) can be obtained as a substantially pure product by performing a usual extraction operation or crystallization operation, but it can be purified by other methods.
- R 1 is a hydrogen atom
- R 2 is a trityl group
- R 3 is a hydrogen atom.
- Table 1 shows the results of the same reaction as in Example 1 except that the reaction solvent was changed and the reaction time was adjusted accordingly. ⁇ table 1 ⁇
- Table 2 shows the results of the same reaction as in Example 1 except that the concentration of perchloric acid was changed and the reaction time was adjusted.
- Table 3 shows the results of the same reaction as in Example 1 except that the proton acids were changed to the following acids. [Table 3]
- Example 2 The same reaction as in Example 1 was carried out except that the compound (la) was changed to a compound (lb, R 1 : trityl group, R 2 trityl group, R 3 hydrogen atom), and the result was that the formula (2) was obtained in a yield of 91%. ) Was obtained.
- the 1H N MR of the obtained cefdir compound was consistent with that of Example 1.
- an acid-labile Cefdier compound is combined with an organic protonic acid in an amount necessary for hydrogen bonding and a small amount of a perhalogenated acid to form a hydrogen bond with a weak acid and a deprotection with a strong acid in an organic solvent.
- a subtle combination it has become possible to produce acid-unstable Cefdiryl compounds in high yield and high purity.
- a post-treatment is simple and an industrially extremely easy method for producing a cefdinir compound can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01919924A EP1273587B1 (en) | 2000-04-13 | 2001-04-13 | Process for the preparation of a 3-vinylcephem compound |
HK03100146.0A HK1048112B (zh) | 2000-04-13 | 2003-01-07 | 3-乙烯基-頭孢化合物的製備方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-111448 | 2000-04-13 | ||
JP2000111448A JP4544692B2 (ja) | 2000-04-13 | 2000-04-13 | 3−ビニル−セフェム化合物の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001079211A1 true WO2001079211A1 (fr) | 2001-10-25 |
Family
ID=18623771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003182 WO2001079211A1 (fr) | 2000-04-13 | 2001-04-13 | Procede de preparation d'un compose 3-vinylcepheme |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1273587B1 (ja) |
JP (1) | JP4544692B2 (ja) |
KR (1) | KR100458233B1 (ja) |
CN (1) | CN1134446C (ja) |
HK (1) | HK1048112B (ja) |
WO (1) | WO2001079211A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003091261A1 (en) * | 2002-04-26 | 2003-11-06 | Ranbaxy Laboratories Limited | Process for the preparation of cefdinir |
WO2004046154A1 (en) * | 2002-11-15 | 2004-06-03 | Orchid Chemicals & Pharmaceuticals Ltd | Novel amorphous hydrate of a cephalosporin antibiotic |
US7105659B2 (en) * | 2003-06-02 | 2006-09-12 | Aurobind - Pharma Ltd. | Process for preparing cefdinir |
US7250508B2 (en) | 2002-08-13 | 2007-07-31 | Sandoz Ag | Cefdinir intermediate |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20022076A1 (it) * | 2002-10-01 | 2004-04-02 | Antibioticos Spa | Sali di intermedi del cefdinir. |
ITMI20022724A1 (it) * | 2002-12-20 | 2004-06-21 | Antibioticos Spa | Sali cristallini del cefdinir. |
WO2004104010A1 (en) * | 2003-05-20 | 2004-12-02 | Ranbaxy Laboratories Limited | Crystalline form of cefdinir |
CN101565427B (zh) * | 2009-06-11 | 2011-04-27 | 浙江昂利康制药有限公司 | 头孢地尼的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105459A2 (en) * | 1982-09-30 | 1984-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Syn-isomer of 7-substituted-3-vinyl-3-cephem compounds, processes for production thereof and pharmaceutical compositions containing them |
WO1996026943A1 (en) * | 1995-02-27 | 1996-09-06 | F.Hoffmann-La Roche Ag | Derivatives of 3-pyrrolidylidene-2-one-cephalosporines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA836918B (en) * | 1982-09-30 | 1984-05-30 | Fujisawa Pharmaceutical Co | 7-substituted-3-vinyl-3-cephem compounds and processes for the production of the same |
US6093814A (en) * | 1995-12-27 | 2000-07-25 | Hanmi Pharmaceutical Co., Ltd. | Process for preparation of cefdinir |
US20060040915A1 (en) * | 2002-04-26 | 2006-02-23 | Yatendra Kumar | Process for the preparation of cefdinir |
-
2000
- 2000-04-13 JP JP2000111448A patent/JP4544692B2/ja not_active Expired - Lifetime
-
2001
- 2001-04-13 WO PCT/JP2001/003182 patent/WO2001079211A1/ja active Application Filing
- 2001-04-13 KR KR10-2001-7015779A patent/KR100458233B1/ko active IP Right Grant
- 2001-04-13 EP EP01919924A patent/EP1273587B1/en not_active Expired - Lifetime
- 2001-04-13 CN CNB018009204A patent/CN1134446C/zh not_active Expired - Lifetime
-
2003
- 2003-01-07 HK HK03100146.0A patent/HK1048112B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105459A2 (en) * | 1982-09-30 | 1984-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Syn-isomer of 7-substituted-3-vinyl-3-cephem compounds, processes for production thereof and pharmaceutical compositions containing them |
WO1996026943A1 (en) * | 1995-02-27 | 1996-09-06 | F.Hoffmann-La Roche Ag | Derivatives of 3-pyrrolidylidene-2-one-cephalosporines |
Non-Patent Citations (1)
Title |
---|
See also references of EP1273587A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003091261A1 (en) * | 2002-04-26 | 2003-11-06 | Ranbaxy Laboratories Limited | Process for the preparation of cefdinir |
EP1546154A1 (en) * | 2002-04-26 | 2005-06-29 | Ranbaxy Laboratories, Ltd. | Process for the preparation of cefdinir |
EP1546154A4 (en) * | 2002-04-26 | 2008-03-26 | Ranbaxy Lab Ltd | METHOD FOR THE PRODUCTION OF CEFDINIR |
US7250508B2 (en) | 2002-08-13 | 2007-07-31 | Sandoz Ag | Cefdinir intermediate |
US7825241B2 (en) | 2002-08-13 | 2010-11-02 | Sandoz Ag | Cefdinir intermediate |
WO2004046154A1 (en) * | 2002-11-15 | 2004-06-03 | Orchid Chemicals & Pharmaceuticals Ltd | Novel amorphous hydrate of a cephalosporin antibiotic |
US7244842B2 (en) * | 2002-11-15 | 2007-07-17 | Orchid Chemicals & Pharmaceuticals Ltd. | Amorphous hydrate of a cephalosporin antibiotic |
US7105659B2 (en) * | 2003-06-02 | 2006-09-12 | Aurobind - Pharma Ltd. | Process for preparing cefdinir |
Also Published As
Publication number | Publication date |
---|---|
EP1273587A4 (en) | 2007-12-26 |
KR100458233B1 (ko) | 2004-11-26 |
JP4544692B2 (ja) | 2010-09-15 |
JP2001294590A (ja) | 2001-10-23 |
HK1048112A1 (en) | 2003-03-21 |
EP1273587B1 (en) | 2009-06-10 |
CN1134446C (zh) | 2004-01-14 |
EP1273587A1 (en) | 2003-01-08 |
KR20020032430A (ko) | 2002-05-03 |
HK1048112B (zh) | 2004-11-26 |
CN1366527A (zh) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001096301A1 (fr) | Procedes de production de derive de piperidine racemique et de production de derive de piperidine a activite optique | |
JP5410578B2 (ja) | シラスタチン酸の改善された製造方法 | |
US7148355B2 (en) | Process for the preparation of repaglinide | |
WO2001079211A1 (fr) | Procede de preparation d'un compose 3-vinylcepheme | |
KR102167614B1 (ko) | 가도부트롤의 제조방법 | |
IE50176B1 (en) | Process for the production of phenylglycyl chloride hydrochlorides | |
CN101245078B (zh) | 头孢噻呋的双苄基乙二胺盐及其制备方法和应用 | |
KR100343434B1 (ko) | 7-아미노-3-메톡시메틸-3-세펨-4-카복실산의 제조방법 | |
JPS61263984A (ja) | β−ラクタム誘導体の製造方法 | |
JP2000026470A (ja) | 3−セフェム化合物の製造方法 | |
JP2018525376A (ja) | クロマノール誘導体の新規な製造方法 | |
JPH11124384A (ja) | 3−セフェム化合物の製造法 | |
US7476760B2 (en) | Purification and production methods of 1-aminocyclopropanecarboxylic acid | |
KR100472048B1 (ko) | 아즈트레오남의 신규제조방법 | |
JP2002371060A (ja) | 光学活性アミノピペリジン誘導体の製造方法 | |
US20040002601A1 (en) | Method for producing cephalosporins | |
US6313315B1 (en) | Methods for producing N-protected-azetidine-2-carboxylic acids | |
WO2004063141A1 (ja) | 光学活性ジアシル酒石酸の回収方法 | |
EP1043320A1 (en) | New process for producing aminopiperazine derivatives | |
JP4168416B2 (ja) | 光学活性アミノペンタンニトリルの製造方法 | |
WO2002085913A1 (fr) | Compose de penicilline et de cephalosporine | |
JP2814286B2 (ja) | 2―エキソメチレンペナム誘導体の製造法 | |
JP2001252569A (ja) | 高分子固定化キラルジルコニウム触媒 | |
JPH07149731A (ja) | 5−アリールヒダントイン化合物およびその誘導体の製造方法 | |
JP2001081083A (ja) | N−炭化水素オキシカルボニルアラニルアミノチアゾール酢酸エステル誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 01800920.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017015779 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001919924 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001919924 Country of ref document: EP |